Development and evaluation of controlled porosity osmotic pump for Nifedipine and Metoprolol combination

Table 8 Predicted in vivo performance of the developed formulation for NP and MP

Predicted parameters	NP		PD (%)	MP		PD (%)
	Desired^a	Formulation^b*		Desired^c	Formulation^d*
Cmax (ng/ml) after a single dose study	55.85	51.83	-7.2	44.85	42.08	-6.1
Cmax (ng/ml) at steady state	60.68	58.0	-4.4	49	45.98	-6.1
Tmax (h)	5.19	5.18	-.19	8.921	8.906	-0.16
Cmin (ng/ml) at steady state	15.16	14.8	-2.3	26	25	-3.8
AUC _0-t (ng h/ml) after a single dose study	405	374	-7.6	357	334	-6.4
AUC _0-t (ng h/ml) at steady state	669	639	-4.6	661	619	-6.3

^a Predicted from desired zero-order delivery profile (NP) (dose = 20 mg, R⁰ = 1.677 mg/h, and t_del = 5.19 h).
^b* Predicted from drug release studies (NP-Formulation CF6) (dose = 20.13 mg, R⁰ = 1.479 mg/h, and t_Del = 5.18 h).
^cPredicted from desired zero-order delivery profile (MP) (dose = 50 mg, R⁰ = 4.20 mg/h, and t_Del = 8.79 h).
^d* Predicted from drug release studies (MP-Formulation CF6) (dose = 50.49 mg, R⁰ = 3.94 mg/h, and t_Del = 8.90 h).

ISSN: 1476-511X